PTG-100 for Patients With Celiac Disease

N

Nielsen Fernandez-Becker

Status and phase

Completed
Phase 1

Conditions

Celiac Disease

Treatments

Drug: Placebo
Drug: PTG-100

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04524221
57613
PTG-100-05-CeD (Other Identifier)

Details and patient eligibility

About

The goal of this study is to learn whether or not the drug PTG-100 can reduce or prevent inflammatory injury to the small intestine that occurs when people with celiac disease eat food products containing gluten. This is a clinical research study to determine the safety and efficacy of PTG-100 in preventing gluten-induced inflammatory injury to the small intestine in patients with celiac disease. 30 patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days. They will also receive a gluten challenge twice daily in the form of a cookie or equivalent. An upper gastrointestinal endoscopy and exam including small bowel mucosa biopsy will be performed at the start of the treatment period and again at the end. Blood samples will be routinely taken to evaluate safety and the drug's mechanism of action throughout the study, and symptoms will be recorded using the celiac symptoms index (CSI) survey.

Enrollment

12 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of celiac disease

Exclusion criteria

  • Active GI disease or history of clinically significant diseases
  • Diagnosis of Crohn's disease or ulcerative colitis.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

12 participants in 2 patient groups, including a placebo group

PTG-100
Experimental group
Description:
Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
Treatment:
Drug: PTG-100
Placebo
Placebo Comparator group
Description:
Patients will receive either placebo (fake drug) or PTG-100 (real drug) in capsule form twice daily for 42 days.
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems